Altered function of the alpha7 nicotinic acetylcholine receptor (α7-nAChR) is implicated in several neuropsychiatric diseases. Nevertheless, studies of the human cerebral α7-nAChR even in healthy aging are limited in number and to postmortem tissue. Methods: The distribution of the cerebral α7-nAChR was estimated in nine brain regions in 25 healthy volunteers (ages 21-86 years; median 57 years, interquartile range 52 years) using [ 18 F]ASEM with positron emission tomography (PET) imaging. Regional total distribution volume (V T ) measurements were calculated using the Logan method from each subject's 90 min dynamic PET data and their metabolite-corrected plasma input function. Spearman's rank or Pearson's correlation analysis was used depending on the normality of the data. Correlation between age and regional 1) volume relative to intracranial volume (volume ratio) and 2) [
F]ASEM V T and neuropsychological measures was investigated in a subpopulation of 15 elderly healthy participants (those 50 years of age and older). Bonferroni correction for multiple comparisons was applied to statistical analyses. Results: A negative correlation between tissue volume ratio and age was observed in six of the nine brain regions including striatum and five cortical (temporal, occipital, cingulate, frontal, or parietal) regions. A positive correlation between [
18 F]ASEM V T and age was observed in all nine brain regions of interest (ROIs). There was no correlation between [ 18 F]ASEM V T and volume ratio in any ROI after controlling for age. Regional [
18 F]ASEM V T and neuropsychological performance on each of eight representative subtests were not correlated among the wellperforming subpopulation of elderly healthy participants. Conclusions: Our results suggest an increase in cerebral α7-nAChR distribution over the course of healthy aging that should be tested in future longitudinal studies. The preservation of the α7-nAChR in the aging human brain supports the development of therapeutic agents that target this receptor for use in the elderly. Further study of the relationship between α7-nAChR availability and cognitive impairment over aging is needed.
Introduction
The alpha7 nicotinic acetylcholine receptor (α7-nAChR) is expressed on neurons and has functional roles in synaptic transmission, neurotransmitter release, intracellular signaling, and synaptic plasticity that collectively mediate cognitive function (Wallace and Porter, 2011) . Human post-mortem studies support altered distribution of the cerebral α7-nAChR in neuropsychiatric illness, including studies of schizophrenia (Freedman et al., 1995; Marutle et al., 2001 ) and Alzheimer's disease (Guan et al., 2000) . Since there is evidence implicating the α7-nAChR in various disease processes, the utility of new therapies targeting the α7-nAChR is being evaluated in patient populations with cognitive or affective symptoms (D'Hoedt and Bertrand, 2009; Hurst et al., 2013; Mazurov et al., 2011 Mazurov et al., , 2012 Olincy et al., 2006; Shytle et al., 2002; Taly and Charon, 2012) . Nevertheless, our understanding of the availability of the α7-nAChR even in healthy aging is incomplete since studies of human brain tissue that focus on this receptor subtype are limited in number and to a narrow selection of examined regions . New techniques designed to image the α7-nAChR in vivo promise to help elucidate changes in the distribution of the cerebral α7-nAChR in healthy aging and disease (Horti, 2015; Horti et al., 2014) .
A radioligand for imaging the α7-nAChR, [ 18 F]ASEM, was developed by our group (Horti, 2015) and has shown promising pharmacokinetic characteristics in early human neuroimaging studies using positron emission tomography (PET) (Hillmer et al., 2017; Wong et al., 2014) . [
18 F]ASEM enters the brain rapidly and within 15-30 min after intravenous (IV) bolus radiotracer injection the standardized uptake values peak around 3.0-4.5 before gradual decline in all regions. Two recent studies using this radiotracer in human neuroimaging support the use of graphical analysis (plasma reference graphical analysis [PRGA] , multilinear analysis method [MA1]) to derive the primary binding outcome, regional total distribution volume (V T ), using data from at least 90 min of dynamic imaging (Hillmer et al., 2017; Wong et al., 2014) . The test-retest variability of [ 18 F]ASEM human PET data was 10.8 ± 5.1% and 11.7 ± 9.8% across the brain regions tested in these two independent studies of healthy controls.
Here, we aimed to use [ 18 F]ASEM PET-based neuroimaging in a new group of healthy individuals to investigate the availability of the α7-nAChR within the context of healthy aging. We focused on the binding of [ 18 F]ASEM in nine regions, including those suspected to have lower (thalamus, frontal cortex) or unchanged (hippocampus, striatum) availability of the α7-nAChR in the aged brain based on limited results using α-bungarotoxin or assay of mRNA in human postmortem tissue (Court et al., 1997; Hellstrom-Lindahl and Court, 2000; Nordberg and Winblad, 1986; Utsugisawa et al., 1999) . Since decline in cholinergic signaling is seen across the lifespan and may be linked to compensatory redistribution of the α7-nAChR or to cognitive deficits in elderly individuals, we also assessed the relationship between regional [
18 F]ASEM V T and 1. Regional brain volume as well as 2. Cognitive performance, the latter among the subset of participants who were 50 years of age or older.
Materials and methods

Human subjects
A Johns Hopkins Institutional Review Board approved this study and all participants provided written informed consent. Use of [ 18 F]ASEM is conducted under a FDA exploratory IND. Healthy adult (over age 18 years) participants were recruited through local advertising. Each subject completed a careful clinical interview and physical assessment with screening blood work, electrocardiogram (EKG), and urine toxicology. Eligibility criteria included stable health, with no clinical abnormality on a screening health assessment and the structural magnetic resonance imaging (MRI). Exclusion criteria included nicotine use, any current or past psychiatric or neurological illness (including history of head injury with loss of consciousness), history of recreational substance abuse including marijuana (assessed by self-report and urine toxicology), prescribed medication known to affect acetylcholine signaling (including but not limited to anticholinergic and certain 5HT 3 anti-emetic medications), any current psychotropic medication use, contraindication to MRI (i.e. implanted metal, claustrophobia), or contraindication to PET imaging with arterial line placement (i.e. clotting factor deficiency, pregnancy/breast feeding, prior radiation exposure). Participants completed the Mini Mental State Examination (MMSE) (Folstein et al., 1975) to assess global cognitive performance. Older participants (age 50 years and older) in this study were also assessed using a battery of neuropsychological tests. We chose to focus on eight representative subtests from this comprehensive battery to characterize performance of these elderly participants across the neurocognitive domains of attention [ were completed using the CFX Manager™ Software (Bio-Rad, Hercules, CA). Individuals with at least one ε4 allele were categorized as APOE ε4 carriers.
In vivo brain imaging
Radiotracer synthesis and PET acquisition [ 18 F]ASEM was synthesized as previously described by one-step microwave radiosynthesis via the corresponding nitro-precursor (Gao et al., 2013) , and met all U.S. Pharmacopeia Convention Chapter <823> acceptance testing criteria. Radiochemical purity at end of synthesis was >98% with high specific radioactivity (2306 ± 2164 GBq/μmol) at the time of IV bolus radiotracer injection and onset of the dynamic listmode PET acquisition. The average injected dose of radioactivity was 510.1 ± 41.0 MBq with injected mass of 0.19 ± 0.17 μg.
PET acquisition A thermoplastic mask was fitted to each subject's face for immobilization and positioning of the head during scanning. PET continuous listmode data were acquired using a High Resolution Research Tomograph scanner (HRRT, Siemens Healthcare, Knoxville,TN), an LSO-based, dedicated brain PET scanner with <2.5 mm reconstructed image resolution . Four participants (two females with ages 26 and 82 years, and two males with ages 25 and 67 years) underwent data collection for 120 min. This longer scan time was used to validate further the use of a 90 min emission scan. Ninety min of continuous listmode data were acquired from each subsequent participant. One hundred and twenty min of listmode data were binned into 36 frames (four 15 s, four 30 s, three 1 min, two 2 min, five 4 min, and eighteen 5 min frames). Ninety min of listmode data were binned using the same frame protocol with six less 5 min frames (total of 30 frames). The data were then reconstructed using the iterative ordinary-Poisson ordered-subset expectation-maximization algorithm (6 iteration and 16 subsets, 2 mm post-smoothing), with correction for radioactive decay, dead time, attenuation, scatter and randoms . The attenuation maps were generated from 6 min transmission scans performed with a 137 Cs point source prior to the emission scans. The reconstructed image volume spanned 31 cm Â 31 cm transaxially and 25 cm axially. The image matrix consisted of 256 Â 256 x 207 voxels and a voxel size of 1.22 Â 1.22 Â 1.22 mm 3 .
Plasma sampling
All participants underwent radial arterial line placement prior to radiotracer injection. Measurement of the arterial plasma input function was conducted through collection of 35-50 blood samples (1 mL) that were obtained at the following intervals after bolus radiotracer injection (p.i.): as fast as possible for the initial 1.5 min p.i., every 30 s between 1.5 and 3 min p.i., once at 5 min p.i., and then every 5 min for the duration of the 90 or 120 min continuous emission scan. The fraction of parent radioligand in plasma was determined by high performance liquid chromatography (HPLC) analysis from collection of 3-6 mL blood samples before radiotracer injection (background) and at 5, 10, 20, 30, 45, 60, 75 , and 90 min p.i. Scans lasting 120 min had additional blood sampling for metabolite measurements at 105 and 120 min p.i.
Briefly, the modified column-switching HPLC method (Hilton et al., 2000) used an Agilent Technologies system containing a 1 260 Infinity quaternary pump, a 1 260 Infinity column compartment module, a 1 260 Infinity UV detector, and a Bioscan radiation detector that was controlled by OpenLab CDS EZChrom (A.01.04) software. Each plasma sample (1-2 mL) was loaded onto a 4 mL Rheodyne injector loop and was initially directed to the capture column (packed with Phenomenex Strata-X 33 μm polymeric reversed phase sorbent) and detectors using 1% acetonitrile and 99% water mobile phase at 2 mL/min to detect polar metabolites. After 2 min of elution, an analytical mobile phase composed of 40% acetonitrile and 60% aqueous triethylamine at a concentration of 0.1 M and pH ¼ 7.1 (adjusted with phosphoric acid) was applied to elute trapped non-polar metabolites and parent radiotracer onto an analytical column (Waters, reverse phase XBridge BEH C18 5 μM 4.6 Â 250 mm) at 2 mL/min.
Measurement of Plasma Free Fraction (f P )
Plasma Free Fraction (f P ) was measured using rapid equilibrium dialysis (RED). Plasma samples were isolated by centrifugation from one blood sample obtained from each participant before radiotracer injection. A 300 μL sample of plasma was spiked with 3 μCi of [
18 F]ASEM and added into the sample chamber of Single-Use RED Plate with Inserts (Thermo Scientific, Rockford, IL, USA) with an 8 K molecular-weight cutoff. 500 μL of PBS was added to the buffer chamber and the plate was incubated on an Incubating Microplate Shaker (Fisher Scientific, Waltham, MA, USA) at 37 C for 4 h. 100 μL of plasma and 100 μL of PBS were transferred to a clean tube. All samples were measured in triplicate. The radioactivity was measured using a 2 480 WIZARD 2 Gamma Counter (Perkin Elmer, Waltham, MA, USA) to obtain the radioactivity in the plasma (C P ) and buffer (C U ). The free, unbound fraction (f P ) was calculated as: f P ¼ C U /C P x 100 (%).
MRI acquisition MR structural T1-weighted imaging was acquired on a Siemens MAGNETOM Prisma or on a Siemens MAGNETOM Trio 3 Tesla scanner (Malvern, PA, USA) with a Trio head matrix 12-channel head coil or Prisma head/neck 20-channel head coil, to obtain a 0.8 Â 0.8 Â 0.8 mm 
Data analysis and statistics
Image processing
The software package PMOD (v3.7, PMOD Technologies Ltd, Zurich, Switzerland) was used in the initial PET image processing and kinetic analysis. Inter-frame motion correction was applied post-reconstruction using the motion correction function in PMOD. First, a static reference frame was generated by averaging the frames corresponding to the 30-60 min p.i. Second, the motion correction was accomplished by rigid matching of the dynamic data to the reference image frame by frame. PET-MRI co-registration was completed as previously described (Coughlin et al., 2015) . Cortical reconstruction and volumetric segmentation of T1-weighted MR images were performed with the FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/). Nine regions of interest (ROIs) were selected for this study: thalamus, striatum, hippocampus, cerebellar cortex, temporal cortex, occipital cortex, cingulate cortex, frontal cortex and parietal cortex. Total intracranial volume (ICV) was also defined using FreeSurfer, for use in analyses exploring the correlation between age and ROI volume normalized to ICV, herein referred to as regional volume ratio. Correlation between regional volume ratio and binding of [
18
F]ASEM was also tested. PET time-activity curves (TACs) were generated for all subjects using the ROI definitions.
Calculation of regional total distribution volume (V T )
The primary PET-based regional binding outcome was total distribution volume, V T , defined as the ratio of the concentration of the radioligand in brain tissue to that in plasma at equilibrium (Innis et al., 2007) . The kinetics of [
18 F]ASEM can be modeled using graphical analysis (Hillmer et al., 2017; Wong et al., 2014) . Here, V T within each ROI was estimated using Logan graphical analysis (Logan et al., 1990) with fixed t* ¼ 45 min, which was chosen for its computational simplicity and independence from assumed compartmental characteristics of the data. Regional V T values generated using Logan analysis with metabolite-corrected arterial input function from 120 min dynamic scans among four participants were compared to V T values obtained with data shortening down to 90 min in order to validate further the proposed use of 90 min of continuous PET data. Since the 1TCM yields equal or improved (Hillmer et al., 2017) model suitability compared to two-tissue compartmental modeling (2TCM), regional V T values from the Logan method were compared to those generated using one-tissue compartmental modeling (1TCM) using 90 min data for all 25 individuals. Compartmental modeling used a fixed blood volume of 5%. Plasma free fraction (f P ) was measured for 18 of the 25 subjects, with mean ± standard deviation (SD) ¼ 0.05 ± 0.01. Regional V T corrected for f P (V T /f P ) was calculated as a secondary outcome measure for those individuals with measured f P .
Statistical analysis
Statistical analyses were performed using SPSS Statistics (Version 23.0, IBM Corp., Armonk, NY, USA). Data were checked for outliers, and descriptive statistics were obtained. Normality of the data was assessed using the Shapiro-Wilk test. The relationships between 1) regional [
18 F] ASEM V T values and age (as well as other descriptive variables) and 2) ROI volume ratios and age were tested using Spearman's rank-order correlation analysis since age was found to not be normally distributed across the study population. These analyses were repeated for the secondary binding outcome, regional V T /f P . The threshold for significance for all statistical tests involving regional V T and regional volume measures accounted for the nine ROIs using a Bonferroni adjusted alpha level of 0.0056 per test (approximately ¼ 0.05/9). The threshold for significance in all statistical tests involving the eight representative neuropsychological tests was set as P < 0.0063 (approximately ¼ 0.05/8). Data were expressed as mean ± SD unless otherwise noted.
Results
Human subject participation
Twenty-five healthy participants, ranging in ages from 21 to 86 (Table 2) . Increasing age was not associated with poorer cognitive performance on any of the eight representative tests (Supplemental Table 1 ). Three of the 15 elderly individuals were found to be APOE ε4 carriers.
Regional volumes
ROI volumes as well as ICV are presented in Table 3 . Spearman's rankorder correlation analyses revealed negative correlation between regional volume ratio and age in striatum, temporal cortex, occipital cortex, cingulate cortex, frontal cortex, and parietal cortex (Table 3 , Fig. 1 ). Table 2 ). Using 90 min data, regional V T values from the Logan method were comparable to V T values estimated using the 1TCM (Table 4) . Furthermore, regional V T values from the Logan method highly correlated with those from using the 1TCM (Spearman's rho ¼ 0.945, P < 0.001) (Supplemental Fig. 2 ).
Spearman's rank-order correlation analyses revealed no correlation between K 1 and age in all nine regions of interest. Regional V T values generated using Logan analysis with metabolite-corrected arterial input function from 90 min scan duration were used in all other correlation analyses hereafter, unless otherwise stated.
Spearman's rank-order correlation analyses revealed positive correlation between [
18 F]ASEM regional V T values and age in all nine ROIs (Table 4 , Fig. 2 ). Secondary analyses revealed positive correlation between V T /f P and age in striatum and parietal cortex (Supplemental Table 5 ).
Among the 15 individuals age 50 years and older, there was no significant correlation found between [ 18 F]ASEM V T in any ROI and performance on any of the eight representative cognitive measures after Bonferroni correction. However, without correction for multiplicity, a negative correlation (P < 0.05) between the DKEFS Number Sequencing Time, a test of attention, and [ 18 F]ASEM V T in occipital cortex (rho ¼ À0.534, P ¼ 0.040) was observed, reflecting a trend of poorer performance in those with lower binding in this region (Supplemental Fig. 3 ).
Discussion
The relationship between cognitive decline in healthy aging and cholinergic dysfunction is likely related to complex underlying factors that may include loss of cholinergic projections, deficits in acetylcholine signaling with secondary effects on other neurotransmitter release, or changed distribution of nicotinic receptor subtypes . Converging evidence from pharmacological studies and animal models suggests the important role of the α7-nAChR in cognitive function (Levin, 2012) . The ability to estimate the distribution of the α7-nAChR in vivo using [ 18 F]ASEM with PET imaging may help elucidate the hypothesized link between cerebral α7-nAChR availability and cognitive decline, even over the healthy human lifespan (Horti, 2015; Horti et al., 2014) .
In the present study, we assessed the relationship between the availability of the α7-nAChR and healthy aging. Using non-parametric (Spearman's rank) correlation analysis, a positive correlation between [ 18 F]ASEM V T and age was observed in all nine ROIs, which included cortical and subcortical regions. Consistent with previously reported regional decreases in brain volume over normal aging (De Leon et al., 1997; Driscoll et al., 2009; Tisserand et al., 2004) , we observed a negative correlation between the tissue volume ratio and age in several of these ROIs, namely striatum, temporal cortex, occipital cortex, cingulate cortex, frontal cortex, and parietal cortex. There was no correlation between [ (Freedman, 1994) 9.3 (1.1) 6-10 CVLT (Delis et al., 1987) age. While this study is limited by small sample size, our results support the promising utility of [ 18 F]ASEM neuroimaging to examine the relationship between the distribution of the α7-nAChR, onset of regional brain atrophy, and related clinical changes over the course of healthy aging. Furthermore, these results suggest a link between higher cerebral availability of the α7-nAChR with aging that may prove important to our understanding of cholinergic signaling over the lifespan. Specifically, these results suggest an increase in the cerebral α7-nAChR, perhaps as a compensatory response to lower acetylcholine signaling, over the course of healthy aging that should be tested in animal models and future longitudinal studies. The preservation of the α7-nAChR over normal aging supports the development of therapeutic agents that target this receptor for treatment of cognitive dysfunction in the elderly. This study benefits from several methodological strengths including a larger sample size of [
F]ASEM V T and volume ratio in any ROI after controlling for
18 F]ASEM neuroimaging data from healthy individuals compared to two other recent studies (Hillmer et al., 2017; Wong et al., 2014 (Hillmer et al., 2017; Wong et al., 2014) , yields regional V T estimates that are similar to those from the preferred compartmental tissue model, the 1TCM (Hillmer et al., 2017) , using 90 min of continuous dynamic emission data. One hundred and twenty min of emission data were acquired from four (two young and two elderly) of our 25 healthy participants and data shortening showed that V T estimates from a 90 min scan duration were within 5% of the values estimated from a 120 min scan duration for all ROIs. 18 F]ASEM V T in occipital cortex should be tested further in larger studies of aging individuals with more varied neuropsychological performance given the hypothesized key role of the α7-nAChR in modulating tasks of sustained attention (Young et al., 2004) .
There are some important methodological and biological factors that should be considered and further investigated in future [ 18 F]ASEM PET imaging studies in aging and disease. First, we defined regional V T as our primary binding outcome. Since only free radioligand enters brain, we also measured f P , and calculated regional V T /f P as a secondary outcome measure. The values obtained for f P were 5 ± 1% and therefore very similar to those reported in six healthy participants (7.7 ± 1.3%) by Hillmer et al. However, the correlation between [ 18 F]ASEM binding and age was only observed in striatum and parietal cortex using V T /f P as the binding outcome. Since f P is an independent measurement and may introduce further noise from plasma data, it is possible that [ 18 F]ASEM lacks sensitivity to detect changes in V T /f P in all affected ROIs over aging, especially in the setting of small sample size. On the other hand, the limited number of postmortem studies to-date do not report evidence of higher availability of the α7-nAChR in elderly cases . Since amyloid burden in the brain may also be associated with Fig. 1 . Scatter plots of regional volume relative to total intracranial volume (volume ratio) plotted against age. Spearman's rank-order correlation analyses revealed negative correlation between regional volume ratio (unitless) and age in six (striatum, temporal cortex, occipital cortex, cingulate cortex, frontal cortex, and parietal cortex) of the nine regions of interest. Individual data points are shown for two representative regions including A) Striatum (rho ¼ À0.605, P ¼ 0.001) and B) Parietal Cortex (rho ¼ À0.627, P ¼ 0.001). Significance was set at P < 0.0056 using Bonferroni correction for the nine regions tested. J.M. Coughlin et al. NeuroImage 165 (2018) 118-124 upregulated cerebral expression of the α7-nAChR (Ikonomovic et al., 2009; Nishiyama et al., 2015) , the effect of this potential synergistic relationship should be examined in future in vivo or in vitro studies. Since there were only three individuals found to be APOE4 carriers in this population, we could not sufficiently test for this effect that could be a focus of future studies. 
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